Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

Figure 1

Kaplan-Meier survival curves of 126 melanoma patients with AJCC stages III B and C disease. (a) Survival data of all patients undergoing autologous vaccination. (b) Correlation of survival with delayed type hypersensitivity (DTH) response to unmodified melanoma attained following vaccination. OS: overall survival; DFS: disease free survival.

(a)

(b)